2408841-19-8
2408841-19-8 structure
- Name: PKM2-IN-3
- Chemical Name: PKM2-IN-3
- CAS Number: 2408841-19-8
- Molecular Formula: C21H22O4
- Molecular Weight: 338.40
- Catalog: Research Areas Neurological Disease
- Create Date: 2022-01-14 13:17:06
- Modify Date: 2025-08-25 18:14:25
-
PKM2-IN-3 is a inhibitor of PKM2 kinase with IC50 value of 4.1μM. PKM2-IN-3 exhibits an anti-neuroinflammatory effect by inhibiting PKM2-mediated glycolysis and NLRP3 activation[1].
| Name | PKM2-IN-3 |
|---|
| Description | PKM2-IN-3 is a inhibitor of PKM2 kinase with IC50 value of 4.1μM. PKM2-IN-3 exhibits an anti-neuroinflammatory effect by inhibiting PKM2-mediated glycolysis and NLRP3 activation[1]. |
|---|---|
| Related Catalog | |
| Target |
4.1 μM (PKM2) |
| In Vitro | PKM2-IN-3 inhibit the TNF-α release of LPS-stimulated RAW264.7 macrophages, with IC50 value of 5.2 μM. PKM2-IN-3 exhibited the lowest toxicity with CC50 value of 43.6 μM[1]. PKM2-IN-3 (0.1-100 μM; 20 min) inhibits PKM2 kinase activity in a cell-free molecular level with the IC50 value of 4.1 μm[1]. |
| In Vivo | PKM2-IN-3 (1, 10 mg/kg; i.p.; daily for 3 days ) significantly reverses the LPS-induced mice behavior changes in open field test[1]. PKM2-IN-3 (1, 10 mg/kg, i.v.; inject at 4 hours and 24 hours after ischemia onset) reduces the infarct volume and improves neurological deficits of tMCAO rats[1]. Animal Model: LPS-induced mice (male 6-8 weeks old; 20.0-22.0 g)[1] Dosage: 1, 10 mg/kg Administration: i.p.; daily for 3 days Result: Reversed the LPS-induced mice behavior changes in open field test. Animal Model: tMCAO Sprague-Dawley rats (Male 8-10 weeks old; 250.0-280.0 g)[1] Dosage: 1, 10 mg/kg Administration: i.v.; injected at 4 hours and 24 hours after ischemia onset Result: Reduced the infarct volume and improved neurological deficits of tMCAO rats. |
| References |
| Molecular Formula | C21H22O4 |
|---|---|
| Molecular Weight | 338.40 |
| Hazard Codes | Xi |
|---|